European CHMP recommends approval of nintedanib for treatment of systemic sclerosis associated interstitial lung disease

Nintedanib (Ofev) is currently licensed in the UK for the treatment of idiopathic pulmonary fibrosis. This medicine was designated an orphan medicine and underwent accelerated assessment.

European Medicines Agency